

Piercarlo Sarzi-Puttini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6546016/publications.pdf>

Version: 2024-02-01

326
papers

14,759
citations

19657

61
h-index

28297

105
g-index

335
all docs

335
docs citations

335
times ranked

15746
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR revised recommendations for the management of fibromyalgia. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 318-328.	0.9	880
2	EULAR evidence-based recommendations for the management of fibromyalgia syndrome. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 536-541.	0.9	639
3	From endothelial dysfunction to atherosclerosis. <i>Autoimmunity Reviews</i> , 2010, 9, 830-834.	5.8	432
4	The Prevalence of Fibromyalgia in the General Population: A Comparison of the American College of Rheumatology 1990, 2010, and Modified 2010 Classification Criteria. <i>Arthritis and Rheumatology</i> , 2015, 67, 568-575.	5.6	323
5	Osteoarthritis: An Overview of the Disease and Its Treatment Strategies. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 1-10.	3.4	316
6	Cardiac involvement in systemic lupus erythematosus. <i>Lupus</i> , 2005, 14, 683-686.	1.6	305
7	Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. <i>Nature Reviews Rheumatology</i> , 2020, 16, 645-660.	8.0	279
8	Long-Term Prognosis and Causes of Death in Systemic Lupus Erythematosus. <i>American Journal of Medicine</i> , 2006, 119, 700-706.	1.5	278
9	COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 337-342.	0.8	249
10	AAPT Diagnostic Criteria for Fibromyalgia. <i>Journal of Pain</i> , 2019, 20, 611-628.	1.4	222
11	Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. <i>Autoimmunity Reviews</i> , 2011, 10, 444-454.	5.8	186
12	Immunogenicity and autoimmunity during anti-TNF therapy. <i>Autoimmunity Reviews</i> , 2013, 12, 703-708.	5.8	167
13	Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1202-1210.	0.9	166
14	Chest CT features of coronavirus disease 2019 (COVID-19) pneumonia: key points for radiologists. <i>Radiologia Medica</i> , 2020, 125, 636-646.	7.7	165
15	Autoimmunity and Anti-TNF- α Agents. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 559-569.	3.8	150
16	Adverse Effects Associated with Non-opioid and Opioid Treatment in Patients with Chronic Pain. <i>Clinical Drug Investigation</i> , 2012, 32, 53-63.	2.2	149
17	Serious infections during anti-TNF- α treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , 2009, 8, 266-273.	5.8	148
18	Primary and secondary autoimmune neutropenia. <i>Arthritis Research and Therapy</i> , 2005, 7, 208.	3.5	146

#	ARTICLE	IF	CITATIONS
19	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , 2012, 12, 225-229.	5.8	146
20	New developments in our understanding of DISH (diffuse idiopathic skeletal hyperostosis). <i>Current Opinion in Rheumatology</i> , 2004, 16, 287-292.	4.3	139
21	Extraspinal manifestations of diffuse idiopathic skeletal hyperostosis. <i>Rheumatology</i> , 2009, 48, 1478-1481.	1.9	130
22	TNF- α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 837-846.	3.8	130
23	The genetics of fibromyalgia syndrome. <i>Pharmacogenomics</i> , 2007, 8, 67-74.	1.3	125
24	Is atherosclerosis an autoimmune disease?. <i>BMC Medicine</i> , 2014, 12, 47.	5.5	122
25	Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 979-984.	0.9	119
26	TNF- α , rheumatoid arthritis, and heart failure: a rheumatological dilemma. <i>Autoimmunity Reviews</i> , 2005, 4, 153-161.	5.8	118
27	Etiology of fibromyalgia: The possible role of infection and vaccination. <i>Autoimmunity Reviews</i> , 2008, 8, 41-43.	5.8	116
28	Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 1031-1038.	1.5	114
29	Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome. <i>Arthritis Research and Therapy</i> , 2006, 8, 218.	3.5	114
30	Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia. <i>Journal of Rheumatology</i> , 2005, 32, 1787-93.	2.0	112
31	Safety of tumor necrosis factor α blockers in hepatitis B virus occult carriers (hepatitis B surface) Tj ETQq1 1 0.784314 rgBT /Overlock Research, 2010, 62, 749-754.	3.4	110
32	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2 3.8	3.8	107
33	Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. <i>Arthritis Research and Therapy</i> , 2006, 8, R3.	3.5	105
34	Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 51-56.	0.9	103
35	Cardiovascular involvement in systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , 2009, 8, 281-286.	5.8	103
36	Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal. <i>Autoimmunity Reviews</i> , 2009, 8, 274-280.	5.8	101

#	ARTICLE	IF	CITATIONS
37	Chronic widespread pain in the spectrum of rheumatological diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 165-171.	3.3	100
38	Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity. <i>Rheumatology International</i> , 2014, 34, 1103-1110.	3.0	99
39	Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. <i>Rheumatology</i> , 2009, 48, 834-839.	1.9	94
40	Identification of the Clinical Features Distinguishing Psoriatic Arthritis and Fibromyalgia. <i>Journal of Rheumatology</i> , 2012, 39, 849-855.	2.0	94
41	Behçet's disease and cardiovascular involvement. <i>Lupus</i> , 2005, 14, 723-726.	1.6	93
42	Treatment Strategy in Fibromyalgia Syndrome: Where Are We Now?. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 37, 353-365.	3.4	89
43	Environment and systemic lupus erythematosus: An overview. <i>Autoimmunity</i> , 2005, 38, 465-472.	2.6	85
44	Cyclic alternating pattern: a new marker of sleep alteration in patients with fibromyalgia?. <i>Journal of Rheumatology</i> , 2004, 31, 1193-9.	2.0	83
45	Tumour necrosis factor antagonist therapy and cancer development: Analysis of the LORHEN registry. <i>Autoimmunity Reviews</i> , 2010, 9, 175-180.	5.8	80
46	RESEARCH: Effects of Long-Term Disease-Modifying Antirheumatic Drugs on Endothelial Function in Patients with Early Rheumatoid Arthritis. <i>Cardiovascular Therapeutics</i> , 2010, 28, e53-64.	2.5	79
47	Different effects of biological drugs in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2013, 12, 575-579.	5.8	76
48	The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. <i>Autoimmunity Reviews</i> , 2010, 9, 835-839.	5.8	75
49	Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. <i>Autoimmunity Reviews</i> , 2019, 18, 102398.	5.8	75
50	Five-Year Follow-Up by Transesophageal Echocardiographic Studies in Primary Antiphospholipid Syndrome. <i>American Journal of Cardiology</i> , 2005, 96, 574-579.	1.6	72
51	Thrombotic Risk Factors In Primary Antiphospholipid Syndrome. <i>Stroke</i> , 2005, 36, 1490-1494.	2.0	71
52	The Appropriate Treatment of Chronic Pain. <i>Clinical Drug Investigation</i> , 2012, 32, 21-33.	2.2	70
53	Infections, rheumatism and autoimmunity: The conflicting relationship between humans and their environment. <i>Autoimmunity Reviews</i> , 2008, 8, 1-4.	5.8	67
54	Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. <i>Rheumatology</i> , 2015, 54, 792-797.	1.9	67

#	ARTICLE	IF	CITATIONS
55	Tumor necrosis factor- α , biologic agents and cardiovascular risk. <i>Lupus</i> , 2005, 14, 780-784.	1.6	65
56	Cardiac involvement in systemic rheumatic diseases: An update. <i>Autoimmunity Reviews</i> , 2010, 9, 849-852.	5.8	65
57	Comorbid Conditions in the AMICA Study Patients: Effects on the Quality of Life and Drug Prescriptions by General Practitioners and Specialists. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 31-37.	3.4	64
58	Anti-cyclic citrullinated peptide antibodies in primary Sjogren's syndrome may be associated with non-erosive synovitis. <i>Arthritis Research and Therapy</i> , 2008, 10, R51.	3.5	64
59	Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 69-82.	3.0	64
60	Systemic rheumatic diseases: From biological agents to small molecules. <i>Autoimmunity Reviews</i> , 2019, 18, 583-592.	5.8	64
61	Estrogens in Pregnancy and Systemic Lupus Erythematosus. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 247-256.	3.8	63
62	Efficacy and Safety of Anti-Tumour Necrosis Factor in Elderly Patients with Rheumatoid Arthritis: An Observational Study. <i>Clinical Reviews in Allergy and Immunology</i> , 2010, 38, 90-96.	6.5	63
63	Increased Neural Sympathetic Activation in Fibromyalgia Syndrome. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 109-117.	3.8	62
64	Rheumatic manifestations in inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014, 13, 20-23.	5.8	61
65	No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2005, 65, 970-971.	0.9	60
66	Infliximab-induced lupus in Crohn's disease: a case report. <i>Digestive and Liver Disease</i> , 2003, 35, 814-817.	0.9	58
67	Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools. <i>RMD Open</i> , 2016, 2, e000302.	3.8	57
68	IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1704-1710.	0.9	56
69	Pharmacotherapy of fibromyalgia. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 285-297.	3.3	56
70	Tumour necrosis factor α is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 545-548.	0.9	55
71	Clinical Presentation of Osteoarthritis in General Practice: Determinants of Pain in Italian Patients in the AMICA Study. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 17-23.	3.4	53
72	Tumor necrosis factor "neutralizing therapies improve altered hormone axes: An alternative mode of anti-inflammatory action. <i>Arthritis and Rheumatism</i> , 2006, 54, 2039-2046.	6.7	53

#	ARTICLE	IF	CITATIONS
73	Anti-thyroid antibodies and thyroid dysfunction in rheumatoid arthritis: Prevalence and clinical value. <i>Autoimmunity</i> , 2008, 41, 111-115.	2.6	53
74	Barriers to Pain Management. <i>Clinical Drug Investigation</i> , 2012, 32, 11-19.	2.2	53
75	The 158V Fcγ3b1 receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 716-721.	0.9	52
76	Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey. <i>Arthritis Research and Therapy</i> , 2016, 18, 78.	3.5	52
77	Potential target of infliximab in autoimmune and inflammatory diseases. <i>Autoimmunity Reviews</i> , 2007, 6, 529-536.	5.8	50
78	OxLDL/β2GPI/anti-oxLDL/β2GPI complex and atherosclerosis in SLE patients. <i>Autoimmunity Reviews</i> , 2007, 7, 52-58.	5.8	50
79	Predicting response to anti-TNF treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , 2009, 8, 431-437.	5.8	50
80	Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study. <i>Immunologic Research</i> , 2017, 65, 419-422.	2.9	50
81	A Double-Blind Crossover Study of Two Cyclobenzaprine Regimens in Primary Fibromyalgia Syndrome. <i>Journal of International Medical Research</i> , 1993, 21, 74-80.	1.0	49
82	Multidisciplinary approach to fibromyalgia: What is the teaching?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 311-319.	3.3	49
83	Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. <i>Journal of Rheumatology</i> , 2016, 43, 869-874.	2.0	49
84	Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect. <i>Arthritis Research and Therapy</i> , 2009, 11, R125.	3.5	48
85	Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection. <i>Arthritis Care and Research</i> , 2016, 68, 738-743.	3.4	48
86	Calcium Deposition and Associated Chronic Diseases (Atherosclerosis, Diffuse Idiopathic Skeletal Tj ETQq0 0 0 rgBT /Overlock_10 Tf 50	1.9	47
87	Pain in rheumatoid arthritis: a critical review. <i>Reumatismo</i> , 2014, 66, 18-27.	0.9	47
88	Systemic Lupus Erythematosus, Atherosclerosis, and Autoantibodies. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 351-361.	3.8	46
89	Coronary Flow Reserve and Asymmetric Dimethylarginine Levels: New Measurements for Identifying Subclinical Atherosclerosis in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 1661-1664.	2.0	46
90	Polymyositis/dermatomyositis and infections. <i>Autoimmunity</i> , 2006, 39, 191-196.	2.6	45

#	ARTICLE	IF	CITATIONS
91	Fibromyalgia and Sleep. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 227-239.	3.3	45
92	The influence of fibromyalgia on achieving remission in patients with long-standing rheumatoid arthritis. <i>Rheumatology International</i> , 2017, 37, 2035-2042.	3.0	45
93	Chronic widespread pain: From peripheral to central evolution. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 133-139.	3.3	44
94	Correlation of the score for subjective pain with physical disability, clinical and radiographic scores in recent onset rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2002, 3, 18.	1.9	43
95	Influence of coping skills on health-related quality of life in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 55, 427-433.	6.7	43
96	The CC homozygosis of the $\gamma 174G$ IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2012, 11, 315-320.	5.8	43
97	Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. <i>Autoimmunity Reviews</i> , 2005, 4, 144-152.	5.8	42
98	Developing new classification criteria for diffuse idiopathic skeletal hyperostosis: back to square one. <i>Rheumatology</i> , 2013, 52, 326-330.	1.9	42
99	Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response. <i>Journal of Clinical Immunology</i> , 2015, 35, 550-557.	3.8	42
100	Detection of preclinical impairment of myocardial function in rheumatoid arthritis patients with short disease duration by speckle tracking echocardiography. <i>International Journal of Cardiology</i> , 2012, 160, 8-14.	1.7	41
101	Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 649-657.	3.0	41
102	Autoantibody production in patients treated with anti-TNF- α . <i>Expert Review of Clinical Immunology</i> , 2008, 4, 275-280.	3.0	40
103	Silent cardiovascular involvement in patients with diffuse systemic sclerosis: a controlled cross-sectional study. <i>Arthritis Care and Research</i> , 2013, 65, 274-280.	3.4	40
104	Are the ACR 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria?. <i>Autoimmunity Reviews</i> , 2018, 17, 33-35.	5.8	40
105	An open, randomized comparison study of cyclosporine, cyclosporine + methotrexate and cyclosporine + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. <i>Rheumatology International</i> , 2005, 25, 15-22.	3.0	39
106	TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?. <i>Autoimmunity Reviews</i> , 2018, 17, 24-28.	5.8	39
107	Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 301-305.	0.9	38
108	Switching TNF-alpha antagonists in rheumatoid arthritis: The experience of the LORHEN registry. <i>Autoimmunity Reviews</i> , 2010, 9, 465-469.	5.8	38

#	ARTICLE	IF	CITATIONS
109	Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis. <i>Rheumatology International</i> , 2002, 21, 234-238.	3.0	37
110	Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. <i>Arthritis Research</i> , 2005, 7, R250.	2.0	37
111	Increased cortisol relative to adrenocorticotrophic hormone predicts improvement during anti-tumor necrosis factor therapy in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 976-984.	6.7	37
112	Amputation of Digits or Limbs in Patients with Antiphospholipid Syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 38, 124-131.	3.4	37
113	Prevalence of mixed cryoglobulinaemia syndrome and circulating cryoglobulins in a population-based survey: the Origgio study. <i>Autoimmunity Reviews</i> , 2014, 13, 609-614.	5.8	37
114	Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics register GISEA. <i>Clinical Rheumatology</i> , 2018, 37, 315-321.	2.2	37
115	A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac. <i>Pain and Therapy</i> , 2018, 7, 163-177.	3.2	37
116	Alexithymia and psychological distress in fibromyalgia: prevalence and relation with quality of life. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 70-7.	0.8	36
117	Do Physicians Treat Symptomatic Osteoarthritis Patients Properly? Results of the AMICA Experience. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 38-42.	3.4	35
118	Anti-TNF therapy in a cohort of rheumatoid arthritis patients: Clinical outcomes. <i>Autoimmunity Reviews</i> , 2009, 8, 260-265.	5.8	35
119	Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?. <i>Immunotherapy</i> , 2015, 7, 353-361.	2.0	35
120	Biomarkers of Good EULAR Response to the B Cell Depletion Therapy in All Seropositive Rheumatoid Arthritis Patients: Clues for the Pathogenesis. <i>PLoS ONE</i> , 2012, 7, e40362.	2.5	34
121	Infections in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2017, 29, 323-330.	4.3	34
122	Exploring the complex relationships between infections and autoimmunity. <i>Autoimmunity Reviews</i> , 2008, 8, 89-91.	5.8	33
123	Switching rheumatoid arthritis treatments: An update. <i>Autoimmunity Reviews</i> , 2011, 10, 397-403.	5.8	33
124	The Management of Chronic Pain in Important Patient Subgroups. <i>Clinical Drug Investigation</i> , 2012, 32, 35-44.	2.2	33
125	Diagnosis of fibromyalgia: comparison of the 2011/2016 ACR and AAPT criteria and validation of the modified Fibromyalgia Assessment Status. <i>Rheumatology</i> , 2020, 59, 3042-3049.	1.9	33
126	Relationship between sympathetic activity and pain intensity in fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S53-7.	0.8	33

#	ARTICLE	IF	CITATIONS
127	The heart in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2010, 9, 414-418.	5.8	32
128	Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature. <i>International Journal of Rheumatology</i> , 2011, 2011, 1-6.	1.6	32
129	Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome. <i>Autoimmunity Reviews</i> , 2019, 18, 778-785.	5.8	32
130	How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. <i>Autoimmunity Reviews</i> , 2020, 19, 102574.	5.8	32
131	Diffuse Idiopathic Skeletal Hyperostosis (DISH) and a Possible Inflammatory Component. <i>Current Rheumatology Reports</i> , 2021, 23, 6.	4.7	32
132	Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 857-63.	0.8	32
133	One year in review 2021: fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 3-12.	0.8	32
134	Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 453-461.	3.7	31
135	Central motor control failure in fibromyalgia: a surface electromyography study. <i>BMC Musculoskeletal Disorders</i> , 2009, 10, 78.	1.9	31
136	Early treatment in early undifferentiated arthritis. <i>Autoimmunity Reviews</i> , 2012, 11, 589-592.	5.8	31
137	Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis. <i>Biologics: Targets and Therapy</i> , 2013, 7, 69.	3.2	31
138	Efficacy and Safety of Pregabalin in Patients with Fibromyalgia and Comorbid Depression Taking Concurrent Antidepressant Medication: A Randomized, Placebo-controlled Study. <i>Journal of Rheumatology</i> , 2015, 42, 1237-1244.	2.0	31
139	What is the role of rituximab in the treatment of rheumatoid arthritis?. <i>Autoimmunity Reviews</i> , 2007, 6, 553-558.	5.8	30
140	Is fibromyalgia a discrete entity?. <i>Autoimmunity Reviews</i> , 2012, 11, 585-588.	5.8	30
141	Long-term safety of abatacept in patients with rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2013, 12, 1115-1117.	5.8	30
142	Clinical Comparison of QUANTA Flash dsDNA Chemiluminescent Immunoassay with Four Current Assays for the Detection of Anti-dsDNA Autoantibodies. <i>Journal of Immunology Research</i> , 2015, 2015, 1-8.	2.2	30
143	The role of a chest computed tomography severity score in coronavirus disease 2019 pneumonia. <i>Medicine (United States)</i> , 2020, 99, e22433.	1.0	30
144	Significance of serum IL-9 levels in inflammatory bowel disease. <i>International Journal of Immunopathology and Pharmacology</i> , 2015, 28, 569-575.	2.1	29

#	ARTICLE	IF	CITATIONS
145	Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: Could it be the first step of the treatment?. <i>Autoimmunity Reviews</i> , 2014, 13, 49-53.	5.8	28
146	Immunity, autoimmunity and inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014, 13, 1-2.	5.8	28
147	Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. <i>Clinical Rheumatology</i> , 2017, 36, 753-761.	2.2	28
148	Cardiac imaging techniques in systemic autoimmune diseases. <i>Lupus</i> , 2005, 14, 727-731.	1.6	27
149	Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 712-714.	0.9	27
150	Cardiovascular and autoimmune diseases in females: The role of microvasculature and dysfunctional endothelium. <i>Atherosclerosis</i> , 2015, 241, 259-263.	0.8	27
151	Identifying the symptom and functional domains in patients with fibromyalgia: results of a cross-sectional Internet-based survey in Italy. <i>Journal of Pain Research</i> , 2016, 9, 279.	2.0	26
152	Cannabinoids in the treatment of rheumatic diseases: Pros and cons. <i>Autoimmunity Reviews</i> , 2019, 18, 102409.	5.8	26
153	Measuring psoriatic disease in clinical practice. An expert opinion position paper. <i>Autoimmunity Reviews</i> , 2015, 14, 864-874.	5.8	25
154	Pain in systemic inflammatory rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 42-52.	3.3	25
155	What is the role of rheumatologists in the era of COVID-19?. <i>Autoimmunity Reviews</i> , 2020, 19, 102539.	5.8	25
156	Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. <i>Journal of Autoimmunity</i> , 2021, 116, 102545.	6.5	25
157	Fibromyalgia syndrome: under-, over- and misdiagnosis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 116, 90-97.	0.8	25
158	Pain in fibromyalgia and related conditions. <i>Reumatismo</i> , 2014, 66, 72-86.	0.9	24
159	Pain and systemic lupus erythematosus. <i>Reumatismo</i> , 2014, 66, 33-38.	0.9	24
160	Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy. <i>Journal of Rheumatology</i> , 2005, 32, 1253-8.	2.0	24
161	Diet therapy for rheumatoid arthritis: A controlled double-blind study of two different dietary regimens. <i>Scandinavian Journal of Rheumatology</i> , 2000, 29, 302-307.	1.1	23
162	Interleukin 6 Blockade: Tocilizumab in Psoriatic Arthritis. <i>Journal of rheumatology Supplement</i> , The, 2012, 89, 97-99.	2.2	23

#	ARTICLE	IF	CITATIONS
163	Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores. <i>Joint Bone Spine</i> , 2014, 81, 37-40.	1.6	23
164	The subjective components of the Disease Activity Score 28-joints (DAS28) in rheumatoid arthritis patients and coexisting fibromyalgia. <i>Rheumatology International</i> , 2018, 38, 1911-1918.	3.0	23
165	Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S7-14.	0.8	23
166	The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. <i>Arthritis and Rheumatism</i> , 2013, 65, 88-97.	6.7	22
167	Anti-citrullinated peptide antibodies and rheumatoid factor isotypes in the diagnosis of rheumatoid arthritis: an assessment of combined tests. <i>Clinica Chimica Acta</i> , 2014, 436, 237-242.	1.1	22
168	How to measure chronic pain: New concepts. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 164-186.	3.3	22
169	Extra-intestinal manifestations of inflammatory bowel diseases. <i>Pharmacological Research</i> , 2020, 161, 105206.	7.1	22
170	Old and new criteria for the classification and diagnosis of fibromyalgia: comparison and evaluation. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 3-9.	0.8	22
171	Position paper of Italian rheumatologists on the use of biosimilar drugs. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 1-4.	0.8	22
172	Fibromyalgia: one year in review 2022. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	22
173	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register. <i>Joint Bone Spine</i> , 2014, 81, 508-512.	1.6	21
174	Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis. <i>Medicine (United States)</i> , 2017, 96, e8180.	1.0	21
175	Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab. <i>Immunologic Research</i> , 2021, 69, 309-311.	2.9	21
176	Anti-cytokine antibodies for rheumatic diseases. <i>Current Opinion in Investigational Drugs</i> , 2009, 10, 1204-11.	2.3	21
177	Doctors'™ Insights into the Patient Perspective: A Qualitative Study in the Field of Chronic Pain. <i>BioMed Research International</i> , 2014, 2014, 1-6.	1.9	20
178	Medical cannabis and cannabinoids in rheumatology: where are we now?. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1019-1032.	3.0	20
179	Preclinical Impairment of Coronary Flow Reserve in Patients with Rheumatoid Arthritis. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 392-397.	3.8	19
180	Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. <i>Clinical Rheumatology</i> , 2016, 35, 2649-2656.	2.2	19

#	ARTICLE	IF	CITATIONS
181	The clinical impact of Anti-DFS70 antibodies in undifferentiated connective tissue disease: case reports and a review of the literature. <i>Immunologic Research</i> , 2017, 65, 293-295.	2.9	19
182	Combined therapeutic approach: Inflammatory bowel diseases and peripheral or axial arthritis. <i>World Journal of Gastroenterology</i> , 2009, 15, 2469.	3.3	19
183	Dysfunctional syndromes and fibromyalgia: a 2012 critical digest. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 143-51.	0.8	19
184	One year in review 2016: fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S145-9.	0.8	19
185	Neuroendocrine therapy of fibromyalgia syndrome: an update. <i>Annals of the New York Academy of Sciences</i> , 2010, 1193, 91-97.	3.8	18
186	Clinimetric evaluations of patients with chronic widespread pain. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 249-270.	3.3	18
187	Acetyl-L-carnitine in chronic pain: A narrative review. <i>Pharmacological Research</i> , 2021, 173, 105874.	7.1	18
188	Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 731-8.	0.8	18
189	Hand Osteoarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 47-52.	3.4	17
190	B Lymphocyte intestinal homing in inflammatory bowel disease. <i>BMC Immunology</i> , 2011, 12, 71.	2.2	17
191	Childhood Parental Loss and Bipolar Spectrum in Obese Bariatric Surgery Candidates. <i>International Journal of Psychiatry in Medicine</i> , 2011, 41, 155-171.	1.8	17
192	Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab. <i>Biologics: Targets and Therapy</i> , 2016, 10, 53.	3.2	17
193	OP0006â€¦Influence of autonomic nervous system dysfunction in the genesis of sleep disorders in fibromyalgia patients. , 2017, 35 Suppl 105, 74-80.		17
194	The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. <i>Rheumatology</i> , 2018, 57, vii11-vii22.	1.9	17
195	Osteoarthritis of the Spine. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 38-43.	3.4	16
196	Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review. <i>Autoimmunity</i> , 2014, 47, 287-306.	2.6	16
197	Serological epitope profile of anti-Ro52â€“positive patients with systemic autoimmune rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2015, 17, 365.	3.5	16
198	Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 945-956.	3.0	16

#	ARTICLE	IF	CITATIONS
199	Psoriatic arthritis: From pathogenesis to pharmacologic management. <i>Pharmacological Research</i> , 2019, 148, 104394.	7.1	16
200	Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3050-3055.	2.8	16
201	Psychometric characteristics of the Italian version of the revised Fibromyalgia Impact Questionnaire using classical test theory and Rasch analysis. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, S41-9.	0.8	16
202	Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2017, 84, 525-530.	1.6	15
203	Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients. <i>Rheumatology</i> , 2021, 60, 728-736.	1.9	15
204	Validation of the reflux disease questionnaire for an Italian population of patients with gastroesophageal reflux disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 187-190.	1.6	14
205	Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. <i>Autoimmunity Reviews</i> , 2010, 9, 845-848.	5.8	14
206	Physiopathology of pain in rheumatology. <i>Reumatismo</i> , 2014, 66, 4-13.	0.9	14
207	Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins. <i>Biologics: Targets and Therapy</i> , 2015, 9, 7.	3.2	14
208	Pain in systemic connective tissue diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 53-62.	3.3	14
209	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. <i>Joint Bone Spine</i> , 2018, 85, 455-459.	1.6	14
210	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. <i>Joint Bone Spine</i> , 2021, 88, 105062.	1.6	14
211	Comparison of Efficacy of Ketoprofen and Ibuprofen in Treating Pain in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>Pain and Therapy</i> , 2021, 10, 577-588.	3.2	14
212	Cannabis and Autoimmunity: Possible Mechanisms of Action. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 261-271.	5.8	14
213	The Italian version of the Fibrofatiigue Scale, a reliable tool for the evaluation of fibromyalgia symptoms. <i>Journal of Psychosomatic Research</i> , 2004, 56, 213-216.	2.6	13
214	Hidden musculoskeletal involvement in inflammatory bowel disease: a multicenter ultrasound study. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 84.	1.9	13
215	Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. <i>Autoimmunity Reviews</i> , 2020, 19, 102509.	5.8	13
216	Cardiovascular Consequences of Autoimmune Rheumatic Diseases. <i>Current Vascular Pharmacology</i> , 2020, 18, 566-579.	1.7	13

#	ARTICLE	IF	CITATIONS
217	Fibromyalgia and the concept of resilience. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 116, 105-113.	0.8	13
218	The role of echocardiographic techniques in connective tissue diseases. <i>Autoimmunity Reviews</i> , 2005, 4, 171-177.	5.8	12
219	CC chemokine receptor 5 polymorphism in Italian patients with Behcet's disease. <i>Rheumatology</i> , 2012, 51, 2141-2145.	1.9	12
220	The impact of pain on systemic rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 1-5.	3.3	12
221	The words of pain in complex regional pain syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 71-76.	3.3	12
222	Impact of Moving From a Widespread to Multisite Pain Definition on Other Fibromyalgia Symptoms. <i>Arthritis Care and Research</i> , 2017, 69, 1878-1886.	3.4	12
223	Intestinal microbiota changes induced by TNF-inhibitors in IBD-related spondyloarthritis. <i>RMD Open</i> , 2021, 7, e001755.	3.8	12
224	Overactive lifestyle in patients with fibromyalgia as a core feature of bipolar spectrum disorder. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 122-8.	0.8	12
225	Analysis of Pharmacologic and Nonpharmacologic Prescription Patterns of General Practitioners and Specialists in the AMICA Study. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 24-30.	3.4	11
226	Mycophenolate Mofetil in Lupus Glomerulonephritis: Effectiveness and Tolerability. <i>Annals of the New York Academy of Sciences</i> , 2007, 1110, 516-524.	3.8	11
227	An update on emerging drugs for fibromyalgia treatment. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 357-367.	2.4	11
228	High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. <i>Clinical Rheumatology</i> , 2014, 33, 31-37.	2.2	10
229	The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2127.	4.1	10
230	Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: A prospective long-term follow-up. <i>Autoimmunity</i> , 2008, 41, 87-91.	2.6	9
231	Anti-polymer antibodies are inversely correlated with pain and fatigue severity in patients with fibromyalgia syndrome. <i>Autoimmunity</i> , 2008, 41, 74-79.	2.6	9
232	Resistant Cases of Psoriatic Arthritis: How to Manage Them. <i>Journal of rheumatology Supplement</i> , The, 2009, 83, 73-75.	2.2	9
233	Chronic widespread pain or fibromyalgia? That is the question. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 131-132.	3.3	9
234	Building bridges between doctors and patients: the design and pilot evaluation of a training session in argumentation for chronic pain experts. <i>BMC Medical Education</i> , 2015, 15, 89.	2.4	9

#	ARTICLE	IF	CITATIONS
235	Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , 2015, 93, 79-81.	2.2	9
236	Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate. <i>Advances in Therapy</i> , 2016, 33, 1360-1373.	2.9	9
237	Noninvasive imaging methods for evaluating cardiovascular involvement in patients with rheumatoid arthritis before and after anti-TNF drug treatment. <i>Future Science OA</i> , 2019, 5, FSO396.	1.9	9
238	Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2019, 29, 895-902.	1.8	9
239	Assessment of enthesitis in patients with psoriatic arthritis and fibromyalgia using clinical examination and ultrasound. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 123, 31-39.	0.8	9
240	Physical and Rehabilitative Approaches in Osteoarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 62-69.	3.4	8
241	Anti-tumour necrosis factor antibody treatment does not change serum levels of cortisol binding globulin in patients with rheumatoid arthritis but it increases androstenedione relative to cortisol. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1353-1356.	0.9	8
242	Twelve yearsâ€™ experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 213-222.	3.0	8
243	Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA. <i>Joint Bone Spine</i> , 2016, 83, 721-725.	1.6	8
244	Features of mood associated with high body weight in females with fibromyalgia. <i>Comprehensive Psychiatry</i> , 2018, 80, 57-64.	3.1	8
245	Anti-tumour necrosis factor- α antibodies and B cell homeostasis in human inflammatory bowel diseases. <i>International Immunopharmacology</i> , 2018, 54, 329-335.	3.8	8
246	Psoriatic Arthritis and Metabolic Syndrome: Is There a Role for Disease Modifying Anti-Rheumatic Drugs?. <i>Frontiers in Medicine</i> , 2021, 8, 735150.	2.6	8
247	The Italian Society for Rheumatology clinical practice guidelines for the diagnosis and management of fibromyalgia. Best practices based on current scientific evidence. <i>Reumatismo</i> , 2021, 73, 89-105.	0.9	8
248	Predicting Severe/Critical Outcomes in Patients With SARS-CoV2 Pneumonia: Development of the prediCtion severe/critical outcome in COVID-19 (CRITIC) Model. <i>Frontiers in Medicine</i> , 2021, 8, 695195.	2.6	8
249	Rituximab treatment for Sjogren syndrome-associated non-Hodgkinâ€™s lymphoma: case series. <i>Rheumatology International</i> , 2012, 32, 3281-3284.	3.0	7
250	What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis?. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1403-1411.	3.1	7
251	Measurement of Serum Klotho in Systemic Sclerosis. <i>Disease Markers</i> , 2017, 2017, 1-7.	1.3	7
252	Cardiovascular Imaging Techniques in Systemic Rheumatic Diseases. <i>Frontiers in Medicine</i> , 2018, 5, 26.	2.6	7

#	ARTICLE	IF	CITATIONS
253	A Proposed Serum Calprotectin IgG Cut-Off Level for Diagnosing Inflammatory Arthritis. <i>Current Rheumatology Reviews</i> , 2017, 13, 93-97.	0.8	7
254	No Correlations Between the Development of Specific IgA and IgM Antibodies Against Anti-TNF Blocking Agents, Disease Activity and Adverse Side Reactions in Patients with Rheumatoid Arthritis. <i>Open Rheumatology Journal</i> , 2013, 7, 75-80.	0.2	7
255	Controversies in rheumatism and autoimmunity. <i>Autoimmunity Reviews</i> , 2012, 11, 555-557.	5.8	6
256	Pain management in cryoglobulinaemic syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 77-89.	3.3	6
257	Novel pharmaceutical options for treating fibromyalgia. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 559-565.	3.1	6
258	Comparison of methods and TAT assessment: Volumetric AQUIOS CL and bead-based FACS CANTO II cytometers. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 674-678.	1.5	6
259	Biosimilars vs originators: Are they the same?. <i>Autoimmunity Reviews</i> , 2019, 18, 102404.	5.8	6
260	Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 123, 53-59.	0.8	6
261	Vaccination against SARS-CoV-2 in patients with rheumatic diseases: doubts and perspectives. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 196-202.	0.8	6
262	Visceral Hypersensitivity Is Not a Feature of Fibromyalgia Syndrome. <i>Journal of Musculoskeletal Pain</i> , 2001, 9, 47-55.	0.3	5
263	The Characteristics of Symptomatic Osteoarthritis in General and Specialist Practice in Italy: Design and Methods of the AMICA Study. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 11-16.	3.4	5
264	Anti-TNF therapy restores the hypothalamic-pituitary-adrenal axis. <i>Annals of the New York Academy of Sciences</i> , 2010, 1193, 179-181.	3.8	5
265	Cardiovascular injury in systemic autoimmune diseases: an update. <i>Internal and Emergency Medicine</i> , 2011, 6, 99-102.	2.0	5
266	Costs of pain in Rheumatology. <i>Reumatismo</i> , 2014, 66, 103-107.	0.9	5
267	Differences in depression, anxiety and stress disorders between fibromyalgia associated with rheumatoid arthritis and primary fibromyalgia. <i>Stress and Health</i> , 2021, 37, 255-262.	2.6	5
268	The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab015.	0.7	5
269	Heart, rheumatism and autoimmunity: an old intriguing link. <i>Lupus</i> , 2005, 14, 643-645.	1.6	4
270	Organ specific-autoantibodies: Their role as markers and predictors of disease. <i>Autoimmunity</i> , 2008, 41, 1-10.	2.6	4

#	ARTICLE	IF	CITATIONS
271	Why wait? Explaining delays in seeking therapy for early arthritis. <i>Nature Reviews Rheumatology</i> , 2012, 8, 190-191.	8.0	4
272	Possible relationship between certolizumab pegol and arrhythmias: report of two cases. <i>Reumatismo</i> , 2016, 68, 104-108.	0.9	4
273	The safety of pregabalin in the treatment of fibromyalgia. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1541-1548.	2.4	4
274	Unresolved and critical issues in autoimmune rheumatic diseases. <i>Autoimmunity Reviews</i> , 2017, 16, 1093-1095.	5.8	4
275	Controlled-release pregabalin in the treatment of fibromyalgia. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 617-623.	2.8	4
276	New biological treatments for psoriatic arthritis. <i>Israel Medical Association Journal</i> , 2014, 16, 643-5.	0.1	4
277	Childhood adversities in patients with fibromyalgia: are they related to comorbid lifetime major depression?. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 105, 112-118.	0.8	4
278	Chapter 27 Modulation of Hormone Axes by Anti-TNF Therapy. <i>Handbook of Systemic Autoimmune Diseases</i> , 2008, 9, 301-308.	0.1	3
279	Unusual B cell morphology in inflammatory bowel disease. <i>Pathology Research and Practice</i> , 2012, 208, 387-391.	2.3	3
280	Morphological distribution of Î¼ chains and cd15 receptors in colorectal polyp and adenocarcinoma specimens. <i>BMC Clinical Pathology</i> , 2013, 13, 8.	1.8	3
281	Pain in rheumatic diseases: how relevant is it?. <i>Reumatismo</i> , 2014, 66, 1-3.	0.9	3
282	The therapeutic journey of biologic agents: There will be an end?. <i>Pharmacological Research</i> , 2019, 147, 104340.	7.1	3
283	Predictive validity of the 5-item Compliance Questionnaire for Rheumatology (CQR5) in detecting poor adherence of patients with rheumatoid arthritis to biological medication. <i>Arthritis Research and Therapy</i> , 2020, 22, 227.	3.5	3
284	The Co-Morbidity between Bipolar and Panic Disorder in Fibromyalgia Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 3619.	2.4	3
285	Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. <i>Clinical Rheumatology</i> , 2021, 40, 4039-4047.	2.2	3
286	Ankylosing Spondylitis Treatment after First Anti-TNF Drug Failure. <i>Israel Medical Association Journal</i> , 2018, 20, 119-122.	0.1	3
287	Hyperbaric oxygen treatment of fibromyalgia: a prospective observational clinical study. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 116, 63-69.	0.8	3
288	Cardiac Imaging Techniques in Systemic Autoimmune Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2003, , 107-119.	0.1	2

#	ARTICLE	IF	CITATIONS
289	Introduction: Osteoarthritis in the Third Millennium: A New Era for an Old Disease?. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 1-2.	3.4	2
290	Psoriatic arthritis. <i>Annals of the New York Academy of Sciences</i> , 2010, 1193, 176-178.	3.8	2
291	Infections during treatment with biological agents and possible treatment in clinical practice. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 193-195.	3.0	2
292	Somatoform disorders and rheumatic diseases: from DSM-IV to DSM-V. <i>Reumatismo</i> , 2014, 66, 98-102.	0.9	2
293	Psoriatic Arthritis Registries. <i>Journal of rheumatology Supplement, The</i> , 2015, 93, 30-32.	2.2	2
294	Controversies in Rheumatology and Autoimmunity: Approaching the truth by the discussion. <i>Autoimmunity Reviews</i> , 2018, 17, 1-3.	5.8	2
295	Response to Wolfe. Letter to the Editor, "Fibromyalgia Criteria". <i>Journal of Pain</i> , 2019, 20, 741-742.	1.4	2
296	Study of entheses in patients with spondyloarthritis and inflammatory bowel disease with and without fibromyalgia: The importance of ultrasonography. <i>Joint Bone Spine</i> , 2020, 87, 507-508.	1.6	2
297	SERUM CALPROTECTIN LEVELS AS A MARKER OF ARTHRITIS: AN ITALIAN EXPERIENCE. <i>Current Rheumatology Reviews</i> , 2016, 12, 1-1.	0.8	2
298	Acute and chronic pain in orthopaedic and rheumatologic diseases: mechanisms and characteristics. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 105, 127-131.	0.8	2
299	Quantitative evaluation of regional left ventricular wall motion using color kinesis after percutaneous transluminal myocardial revascularization. <i>American Journal of Cardiology</i> , 2001, 87, 896-898.	1.6	1
300	Antigen Preparation for Immunological Studies in Systemic Autoimmune Diseases. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 193-202.	3.8	1
301	Autoimmunity and the Newer Biopharmaceuticals. , 2014, , 795-802.		1
302	Toxicological considerations in the treatment of axial spondylo-arthritis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 663-672.	3.3	1
303	Covid vaccination in patients with autoimmune diseases treated with mycophenolate: Let's think back to the recommendations. <i>Autoimmunity Reviews</i> , 2021, 20, 102908.	5.8	1
304	Rheumatoid Arthritis disease activity assessment in routine care: performance of the most widely used composite disease activity indices and patient-reported outcome measures. <i>Acta Biomedica</i> , 2021, 92, e2021238.	0.3	1
305	Exercise therapy in fibromyalgia patients: comparison of a web-based intervention with usual care. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 123, 86-93.	0.8	1
306	Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 695-695.	0.8	1

#	ARTICLE	IF	CITATIONS
307	Pyogenic Arthritis of the Facet Joints: A Growing Problem for Patients, A Growing Concern for Clinicians. <i>Seminars in Arthritis and Rheumatism</i> , 2006, 35, 269-270.	3.4	0
308	Rheumatoid Arthritis and the Skin. <i>Handbook of Systemic Autoimmune Diseases</i> , 2006, , 161-183.	0.1	0
309	Diagnosis of cardiac involvement in systemic autoimmune diseases. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 839-843.	3.0	0
310	AUTOIMMUNITY AND THE NEWER BIOPHARMACEUTICALS. , 2007, , 783-791.		0
311	Is It Antiphospholipid Syndrome?. <i>International Journal of Rheumatology</i> , 2010, 2010, 1-4.	1.6	0
312	Echocardiographic approach in systemic autoimmune diseases. <i>Journal of Cardiovascular Echography</i> , 2011, 21, 152-156.	0.4	0
313	Update on fibromyalgia. <i>Italian Journal of Medicine</i> , 2012, , 14-20.	0.3	0
314	Reply. <i>Arthritis Care and Research</i> , 2013, 65, 2063-2063.	3.4	0
315	Early psoriatic arthritis: should we treat it in the same way as we treat rheumatoid arthritis?. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 399-408.	0.3	0
316	Cardiac Imaging Techniques in Systemic Autoimmune Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 14, 183-207.	0.1	0
317	New Cardiac Imaging Tools and Invasive Techniques in Systemic Autoimmune Diseases (Part II). <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 14, 209-226.	0.1	0
318	Spondyloarthritis and Gastrointestinal Involvement. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 13, 349-361.	0.1	0
319	Neurobiological similarities between RA and fibromyalgia. <i>Nature Reviews Rheumatology</i> , 2018, 14, 324-325.	8.0	0
320	Conventional and Biological DMARDs in Systemic Rheumatic Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2018, 15, 161-182.	0.1	0
321	Biologics and Biosimilars. , 2019, , 625-628.		0
322	Clinimetrics of Fibromyalgia Syndrome. , 2021, , 223-243.		0
323	Differential Diagnosis of Vasovagal Syncope: Fibromyalgia. , 2015, , 213-221.		0
324	Prise en charge de l'infection par le virus de l'hépatite B chez les patients atteints de polyarthrite rhumatoïde: conférence de consensus italienne. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2018, 85, 115-120.	0.0	0

#	ARTICLE	IF	CITATIONS
325	Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 695.	0.8	0
326	Concerns about the taxonomy, definition and coding of fibromyalgia syndrome in ICD-11: the potential for negative consequences for patient care and research. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	0